Faculty - Experimental Therapeutics Ph.D. Track

Boyko S Atanassov, PhD, Assistant Professor, Bulgarian Academy of Sciences, Sofia, Bulgaria
Functions and regulation of deubiquitinating enzymes (USPs); Epigenetics; Regulation of gene expression, Molecular mechanism of cancer metastasis.

Dhyan Chandra, PhD, Associate Professor, Jawaharlal Nehru University, New Delhi, India
Heat-shock proteins and cell survival, mitochondrial fragmentation and caspase activation, apoptosis signaling in cancer stem cells.

Gokul Das, PhD, Associate Professor; Baylor College of Medicine
Tumor suppressor protein p53/transcriptional regulation/genomic damage, DNA repair, and cell cycle control/interaction between p53 and estrogen receptor signaling pathways.

John Ebos, PhD, Assistant Professor; University of Toronto
Host- and tumor-mediated mechanisms of antiangiogenic drug resistance and their role in metastatic disease progression.

Jia Fang, PhD, Associate Professor, Shanghai Institute of Biochemistry, Chinese Academy of Sciences, China
Research focuses on molecular dissection of various epigenetic mechanisms and understanding their roles in tumor progression and metastasis, with the goal of identifying novel therapeutic, diagnostic and prognostic modalities.

Michael E. Feigin, PhD, Assistant Professor, SUNY Stony Brook
Exploring the noncoding genome and GPCR signaling networks driving pancreas and breast cancer pathogenesis; 3D modeling of human tumors for therapeutic and mechanistic studies.

Michael V. Fiandalo, Instructor, University of Kentucky. Research is focused on inhibiting the androgen metabolism enzymes that facilitate prostate cancer therapeutic resistance and prostate cancer recurrence.

Barbara Foster, PhD, Professor, UC San Francisco
Prostate cancer; transgenic mouse models; prostate cancer/bone interaction; preclinical testing of novel therapeutic approaches for prevention and treatment of prostate cancer.

David Goodrich, PhD, Professor, UC Berkeley
Elucidating molecular mechanisms underlying tumor suppression by the Rb1 gene, particularly in cell cycle regulation, with the aim of targeting this pathway for cancer therapy

Elizabeth A. Griffiths, MD, Assistant Professor, University of North Carolina School of Medicine
Cancer Epigenetics, Wnt biology, Acute Myeloid Leukemia

Nitai C Hait, PhD, Assistant Professor, Jadavpur University and Bose Institute, Calcutta, India
Research focuses on the role of bioactive sphingolipid metabolites, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) in cancer progression and metastasis, with the aim of targeting these signaling pathways for cancer therapy.

Pamela Hershberger, PhD, Associate Professor, Case Western Reserve University
Exploiting nuclear hormone receptor signaling pathways in the prevention and treatment of lung cancer; drug resistance in lung cancer.

Steven Hochwald, MD, Clinical Chief, Surgical Oncology, New York University School of Medicine
Research involves showing the direct interaction between FAK and IGF-1R signal transduction proteins in mammalian and cancer cells. Has patented the invention of novel small molecules that disrupt FAK and IGF-1R protein interactions.

Wendy Huss, PhD, Associate Professor, Baylor College of Medicine
Targeting the prostate tumor stem cell therapeutically in effort to eliminate the source of recurrent prostate cancer.

Candace S. Johnson, PhD, Professor, Ohio State University
Drug development of novel agents; preclinical tumor models; mechanistic studies on drugs with novel targets; steroid hormones and their potential as an antiproliferative agent and development of novel approaches in prostate cancer.

Pawel Kalinski, MD, PhD, Professor, University of Amsterdam, Amsterdam, The Netherlands
My research aims to develop effective immune therapies of cancer, capable of selectively activating effector and memory-type CTLs and Th1 cells and promoting their selective accumulation in tumor tissues.

Fengzhi Li, PhD, Associate Professor, Beijing
Mechanism of anti-apoptotic protein function and regulation in cancer cells.

Jonathan Lovell, PhD, Associate Professor (University at Buffalo). Current cancer research focus involves light-activated drug delivery and liposome-based vaccine adjuvants.

Donald Mager, PhD, PharmD, PhD, FCP Professor and Vice Chair; Department of Pharmaceutical Sciences (University at Buffalo). Development of models of pharmacological target-mediated drug disposition and dynamics, and the experimental validation of the primary determinants of PK/PD profiles of drugs that exhibit such phenomena

James L. Mohler, MD, Associate Director and Senior Vice President for Translational Research, Chief, Inter-Institutional Academics, Professor of Oncology, and Attending, Department of Urology. Training Medical College of Georgia, Duke University, University of Kentucky, Johns Hopkins University
Activities have focused upon the role for the androgen receptor in prostate cancer recurrence after androgen deprivation therapy and racial differences in prostate cancer aggressiveness.

Ravindra K. Pandey, PhD, Professor, University of Rajasthan, Jaipur, India
Development of “Multifunctional Agents” for tumor imaging and therapy.

Beth Pflug, PhD, Associate Professor; Georgetown University School of Medicine, Washington, DC
The laboratory focuses on understanding tumor signaling and growth regulation in prostate cancer and uses this information to identify novel therapeutic and imaging targets for this disease.

Mukund Seshadri, DDS, PhD, Professor, Scientific Director, Translational Imaging Shared Resource. State University of New York at Buffalo
Research is focused on the use of advanced imaging techniques such as magnetic resonance imaging, (MRI), computed tomography (CT) and optical molecular imaging techniques in preclinical and clinical studies.

Robert Straubinger, PhD, Professor; UC San Francisco. Cell biology and biophysics of membranes and membrane function; use of liposomal drug carriers to improve the efficacy of cancer therapeutics.

Dean Tang, MD, PhD, Professor and Chair, Wayne State University, Detroit, MI
Understanding the molecular and cellular basis of tumor cell heterogeneity and developing novel therapeutics targeting cancer stem cells.

Xinjiang Wang, PhD, Assistant Professor, Weizmann Institute of Science, Rehovot, Israel
Identification of regulators of tumor cell growth control through biochemical and cell-based approaches; development of targeted cancer therapeutics.

Anna Woloszynska-Read, PhD, Assistant Professor, SUNY at Buffalo, Roswell Park Division
Research is focused on the role of genetic and epigenetic changes in bladder and prostate cancer in order to decipher the molecular landscape of the diseases, and to point to novel strategies for improved treatment. Research is also conducted in the area of prostate cancer racial health disparities; specifically, the role of DNA methylation and vitamin D deficiency in aggressiveness of prostate cancer among African-American men.

Yue Wu, PhD, Assistant Professor, China Agricultural University, China
Research is focused on tumor microenvironment and molecular signaling in prostate cancer.

Yuesheng Zhang, MD, PhD, Professor, Zhejiang University School of Medicine, Hangzhou, China; Johns Hopkins University School of Medicine, Baltimore, MD
Non-enzymatic functions of prolidase, modulation of plasma protein degradation for development of protein therapeutics and disease biomarkers, EGFR- and HER2-directed cancer drug discovery and development.